[Radiotherapy in node-positive prostate cancer]

Area of Science:

• Oncology
• Radiation Oncology
• Urologic Oncology

Background:

• Limited data exist for node-positive prostate cancer management, creating treatment uncertainty.
• Current guidelines suggest androgen deprivation therapy (ADT) alone or with radiotherapy.
• Node-positive prostate cancer management requires further investigation.

Purpose of the Study:

• To review radiotherapy's role in definitive, adjuvant, and salvage treatment for node-positive prostate cancer.
• To discuss PET imaging tracers for biochemical recurrence after prostatectomy.
• To evaluate radiotherapy's impact on survival in node-positive prostate cancer.

Main Methods:

• Literature review of retrospective studies and clinical guidelines.
• Analysis of treatment outcomes for radiotherapy in node-positive prostate cancer.
• Discussion of patient selection criteria for adjuvant radiotherapy.

Main Results:

• Retrospective data suggest ADT plus radiotherapy improves survival over ADT alone for definitive treatment.
• Many node-positive prostate cancer patients may achieve long-term survival with aggressive therapy.
• Adjuvant radiotherapy benefits patients with pN1 prostate cancer, particularly those with specific tumor characteristics like 3-4 positive lymph nodes or high-grade disease.

Conclusions:

• Randomized trials are essential to confirm radiotherapy's role in definitive and adjuvant settings for node-positive prostate cancer.
• Further research is needed to optimize treatment strategies for this patient group.
• Aggressive therapeutic approaches, including radiotherapy, show potential for curable outcomes.